Did You Know...
...that Charles Goodyear performed some of his experiments on rubber while in debtor's prison? He was there so often he referred to it as his "hotel". Chronically in debt because of poor business sense and ill health, Goodyear depended on the generosity of friends and family. Even after he unlocked the secret to vulcanizing rubber, he was unable to improve his financial situation. When he died, his estate was $200,000 in debt.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8163916 | Azaadamantane ester and carbamate derivatives and methods of use thereof The invention relates to compounds that are substituted azaadamantane ester and carbamate derivatives, compositions comprising such compounds, and methods of using such compounds and compositions. ... | 04/24/2012 |
| 8097726 | Huperzine a compound for treatment of alzheimer's disease A huperzine A compound is provided. The huperzine A compound has following formula: wherein X comprises O or S, Y comprises —O—, —S—, —CH(R4)—, —C(R4)(R5 | 01/17/2012 |
| 7358244 | Azabicycloalkane compounds This invention provides compounds of formula I: wherein R1, R2, R3, R4, R5, R6 and R7 are as defined in the specification, or a pharmaceutically acc... | 04/15/2008 |
| 7348431 | Tyrosine kinase inhibitors The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The compounds of the instant invention possess a core structure that comprises a... | 03/25/2008 |
| 7265226 | 1-alkyl-4-(3-substitutedphenyl)piperidines 8-Substituted-2,6-methano-3-benzazocines of general structure I in which A is —CH2—OH, —CH2NH2, —NHSO2CH3, and Y is O, S or NOH are useful ... | 09/04/2007 |
| 7262298 | 4-hydroxybenzomorphans 4-Hydroxybenzomorphans containing carboxamide or thiocarboxamide at the 3-position are useful as analgesics, anti-diarrheal agents, anticonvulsants, antitussives and anti-addiction medications. ... | 08/28/2007 |
| 7253283 | Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula ... | 08/07/2007 |
| 7214686 | Pharmaceutical compositions and methods for effecting dopamine release Patients susceptible to or suffering from disorders, such as central nervous system disorders, which are characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attent... | 05/08/2007 |
| 7205300 | Aryl fused azapolycyclic compounds This invention is directed to compounds of the formula (I): and their pharmaceutically acceptable salts, wherein R1, R2, and R3 are as defined herein; intermediates for the synthe... | 04/17/2007 |
| 7186844 | Method for producing cyclic carbamate ester A method for producing a cyclic carbamate ester produces the cyclic carbamate ester by reacting an organic compound having at least two halogen atoms per molecule, an amine having at least two hydrogen atoms on a nitrogen atom, and carbon dioxide. ... | 03/06/2007 |
| 7144882 | Aryl fused azapolycyclic compounds This invention is directed to compounds of the formula (I): and their pharmaceutically acceptable salts, wherein R1, R2, and R3 are as defined herein; intermediates for the synthe... | 12/05/2006 |
| 7122534 | Aryl fused azapolycyclic compounds The present invention relates to compounds of formula (I) and their pharmaceutically acceptable salts, wherein R1, R2, R3 and Z are as defined herein, intermediates in the synthesis of ... | 10/17/2006 |
| 7067261 | Methods and compositions for treatment of central nervous system disorders The invention provides methods of screening for substances having an effect on a nicotine receptor by contacting a cell having a nicotine receptor with a test substance; and determining any increase or decrease in phosphorylation of Janus-Activated Kinase 2 (JAK2). ... | 06/27/2006 |
| 7041674 | Carbamic acid esters with anticholinergic activity A compound of formula 1 wherein X−, A, R1, R2, R3, and R4 may have the meanings given in the claims and in the specification, processes for preparing them, their... | 05/09/2006 |
| 6982271 | Tropane analogs The present invention provides compounds, specifically novel tropane analogs, capable of acting as inhibitors of reuptake of monoamines. In preferred embodiments, these compositions are selective inhibitors of serotonin and/or norepinephrine reuptake. Also provided ... | 01/03/2006 |
| 6951938 | Aryl fused azapolycyclic compounds Pharmaceutical compositions comprising compounds of the formula and their pharmaceutically acceptable salts, wherein R1, R2, and R3 are defined as in the specification, in combination w... | 10/04/2005 |
| 6939867 | β3 agonists and uses thereof Sulfamide compounds having formula (I) are described as well as their use in the treatment of diseases dependent on the signaling pathways associated with β-adrenergic receptors, such as obesity, diabetes, hypertension, gastrointestinal hypo- or hyper-motility and ... | 09/06/2005 |
| 6897310 | Aryl fused azapolycyclic compounds Pharmaceutical compositions comprising compounds of the formula and their pharmaceutically acceptable salts, wherein R1, R2, and R3 are defined as in the specification, in combination w... | 05/24/2005 |
| 6887884 | Aryl fused azapolycyclic compounds Compounds of the formula and their pharmaceutically acceptable salts, wherein R1, R2, and R3 are defined as in the specification, intermediates in the synthesis of such compounds, pharm... | 05/03/2005 |
| 6858624 | Aryl fused azapolycyclic compounds This invention is directed to compounds of the formula (I): and their pharmaceutically acceptable salts, wherein R1, R2, and R3 are as defined herein; intermediates for the synthesis of... | 02/22/2005 |
| 6784186 | Therapeutic compounds This invention relates to novel structural analogues and derivatives of compounds with general analgesic or related pharmacological activity. In particular the invention relates to derivatives of opioid compounds, particularly morphine and related compounds, in whic... | 08/31/2004 |
| 6706702 | Aryl fused azapolycyclic compounds The present invention relates to compounds of formula (I) and their pharmaceutically acceptable salts, wherein R1, R2, R3 and Z are as defined herein, intermediates in the synthesis of su... | 03/16/2004 |
| 6683089 | N-allyoxyethyl-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocine-10-ols The present invention relates to 1,2,3,4,5,6-hexahydro-2,6-methano-3 -benzazocin-10-ols of general formula 1 ##STR1## wherein the groups R1, R2, R3, R4, R5, R6, R7, R8... | 01/27/2004 |
| 6605610 | Aryl fused azapolycyclic compounds Compounds of the formula ##STR1## and their pharmaceutically acceptable salts, wherein R1, R2, and R3 are as defined herein; intermediates for the synthesis of such compounds, pharmaceutical compositions containing such co... | 08/12/2003 |
| 6455538 | 1,2,3,4,5,6-Hexahydro-2,6-methano-3-benzazocin-10-ols Compounds of general formula I ##STR1## wherein X is a single bond, --O--, C-C4 -alkylene, or an alkylene bridge having 1 to 8 carbon atoms which may be branched or unbranched and optionally have one or two oxygen atom(s) anywhere in the bridge... | 09/24/2002 |
| 6423842 | Muscarinic agonists and antagonists The present invention provides novel compounds and pharmaceutical compositions thereof useful in the treatment of pain. The compounds of the present invention are azaadamantanes, azanoradamantanes and azahomoadamantanes.... | 07/23/2002 |
| 6410550 | Aryl fused azapolycyclic compounds Compounds of the formula ##STR1## and their pharmaceutically acceptable salts, wherein R1, R2, and R3 are defined as in the specification, intermediates in the synthesis of such compounds. pharmaceutical compositions conta... | 06/25/2002 |
| 6387921 | Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocines and their use as pharmaceutical compositions Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocines of general formula 1: ##STR1## wherein: R1 and R2, which are identical or different, are each hydrogen, C1 -C6 -alkyl, C1 --C6 -... | 05/14/2002 |
| 6355652 | Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocines and their use as pharmaceutical compositions Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocines of general formula 1: ##STR1## wherein: R1 and R2, which may be identical or different, are each hydrogen, C1 -C6 -alkyl, C1 -C6... | 03/12/2002 |
| 6271379 | Intermediates useful for the synthesis of huperzine A Intermediates useful for the synthesis of huperzine A represented by the structures below, ##STR1## and methods for their synthesis, wherein: R1 is lower alkyl, benzyl, or substituted benzyl; X is a suitable leaving group; Y is an electron withdrawi... | 08/07/2001 |
| 6251916 | Muscarinic agonists and antagonists The present invention provides novel compounds and pharmaceutical compositions thereof useful in the treatment of pain. The compounds of the present invention are azaadamantanes, azanoradamantanes and azahomoadamantanes.... | 06/26/2001 |
| 6245777 | N-(5-phenyl-tetrahydrofuranyl)methyl- and N-(6-phenyl-tetrahydropyranyl)methyl-substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ols The present invention relates to N-(5-phenyl-tetrahydrofuranyl)methyl- and N-(6-phenyl-tetrahydropyranyl)methyl-substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ols of general formula 1, processes for preparing such compounds, pharmaceutical ... | 06/12/2001 |
| 6211372 | Pharmaceutical compositions and methods for use A compound of the formula: ##STR1## wherein X' is nitrogen or carbon bonded to a substituent species characterized as having a sigma m value greater than 0, less than 0 or 0; X is nitrogen or carbon bonded to a substituent species characterized as ha... | 04/03/2001 |
| 6159986 | Compounds and therapy for resisting memory loss in humans Therapies and compounds for the inhibition of memory loss. In one embodiment, a combination of Huperzine A and hypericin is employed.... | 12/12/2000 |
| 6140502 | Heat-based process for the re-racemisation of a (-)-2-phenylmethyl-3,3-dimethyl-piperidin-4-on derivative A process for the re-racemisation of a (-)-2-phenylmethyl-3,3-dimethyl-piperidin-4-on derivative wherein a (-)-2-phenylmethyl-3,3-dimethyl-piperidin-4-on derivative of the formula 8B wherein R2 denotes hydrogen C1 -C6... | 10/31/2000 |
| 6136980 | Method of preparing norbenzomorphane as an intermediate in the preparation of pharmaceutically useful benzomorphane derivatives, in particular (-)-(1R,5S,2"R)-3'-hydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7-benzo morphane The present invention relates to new processes for preparing norbenzomorphan, the central intermediate step in the preparation of pharmaceutically useful benzomorphan derivatives of general formula 1 ##STR1## especially (-)-(1R,5S,2"R)-3'-hydrox... | 10/24/2000 |
| 6124459 | Process for preparing pharmaceutically useful norbenzomorphane derivative The present invention relates to a new process for preparing norbenzomorphane derivatives of general formula 1 ##STR1##... | 09/26/2000 |
| 6124312 | Heterocyclic compounds The present invention provides heterocyclic 2-aza-bicyclo[2.2.1]heptane compounds which are useful for modulating a muscarinic ptor.... | 09/26/2000 |
| 6057446 | Certain 1-aza-tricyclo [3.3.1-13,7 ] decane compounds A compound having the formula: ##STR1## wherein X' is nitrogen or carbon bonded to a substituent species characterized as having a sigma m value greater than 0, less than 0 or 0; X is nitrogen or carbon bonded to a substituent species characterized a... | 05/02/2000 |
| 5990104 | Polycyclic alcaloid-derivatives as NMDA-receptor antagonists Polycyclic alkaloids of formula (I), wherein R1 is H, C1-6 alkyl, or C6-12 aryl optionally substituted with polar groups; R2 and R3 are independently H, OH, C1-6 alkyl, --C(NH)--NH2, ... | 11/23/1999 |
